2016 American Transplant Congress
Management of Recurrent aHUS After Adult Kidney transplantation Despite Eculizumab Prophylaxis.
Background Eculizumab (EZB) is approved by NHSE in the UK for prevention and managment of recurrent aHUS after kidney transplantation. Purpose We report aggressive recurrence…2016 American Transplant Congress
Thrombotic Microangiopathy After Kidney Transplantation: A Rare but Serious Complication.
Universidade Federal de São Paulo, São Paulo, Brazil.
Purposes: Study the clinical characteristics of cases with thrombotic microangiopathy (TMA) in the renal allograft, identify the triggers of this disease and determine its impact…2015 American Transplant Congress
Characteristics and Outcomes of Renal Transplant Recipients With Hemolytic Uremic Syndrome: An OPTN Registry Analysis
Hemolytic uremic syndrome (HUS) accounts for <1% of renal transplants in the US. There is limited data on the characteristics and outcomes of in pediatric…2015 American Transplant Congress
1-Year Safety and Efficacy of Eculizumab in Adult aHUS Patients, With or Without a History of Renal Transplant
Background: Atypical hemolytic-uremic syndrome (aHUS) is a life-threatening, chronic disease of complement-mediated TMA. In aHUS, renal transplantation is associated with post-transplant (TP) TMA and ∼50–70%…
American Transplant Congress abstracts